Home/Neumirna/Ellen Donnelly, PhD

ED

Ellen Donnelly, PhD

CEO

Therapeutic Areas

Neurology Epilepsy Parkinson's Disease

Neumirna Pipeline

Drug	Indication	Phase
NMT.001	Drug-Resistant Epilepsy	Phase 1
Undisclosed	Parkinson's Disease	Preclinical

Leadership Team at Neumirna

Ina Brünig-Traebert, PhD

Peter Rasmussen

Henrik Klitgaard, PhD

Scientific Co-Founder, Board Member

View full Neumirna profile